The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 63.50
Bid: 62.00
Ask: 65.00
Change: 1.00 (1.60%)
Spread: 3.00 (4.839%)
Open: 62.50
High: 63.50
Low: 62.50
Prev. Close: 62.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Glycotest secures $1 million investment

23 Jan 2024 07:00

RNS Number : 5323A
NetScientific PLC
23 January 2024
 

For release on RNS: 07.00, 23 January 2024

 

 

 

 

NetScientific plc

("NetScientific" or the "Company")

 

Liver disease diagnostics company Glycotest secures $1 million investment from Fosun

NetScientific Plc (AIM: NSCI), the deep tech and life sciences VC investment group, announces that its portfolio company Glycotest, Inc. ("Glycotest") has successfully closed a $1 million follow-on investment ("Investment") by Fosun Industrial Co., Limited ("Fosun").

As announced by the Company on 2 May 2023, Fosun agreed to make the Investment as part of a $10 million investment and licensing agreement between the parties in 2019 ("2019 Agreement") upon Glycotest providing Fosun with a licence allowing it direct access to the IP licensed by Glycotest in certain circumstances. Such licence has been procured by Glycotest and as such the remaining investment commitment by Fosun now stands at $2 million, subject to the satisfaction of milestones agreed in the 2019 Agreement.

As a result of the Investment, the Glycotest secured convertible loans, which total $812,448 plus accrued interest, ("2023 CLA") may be converted into preferred shares in Glycotest at the election of Glycotest. The Company understands from Glycotest that it intends to convert such loans pending confirmation from the lender under the 2023 CLA of the treatment of accrued interest thereunder (which interest may be converted into preferred shares or repaid in cash).

Following the Investment and conversion of the 2023 CLA (assuming all accrued interest is converted), the Company's direct stake in Glycotest will be 55.90 per cent, alongside Fosun's interest of 34.75 per cent. and the 2023 CLA interest of 6.16 per cent.

The proceeds of the Investment will, inter alia, support Glycotest in the development and validation of its assays ahead of commercial launch. Such validation is possible after the completion in 2023 of subject enrolment and sample collection in Glycotest's clinical validation study, providing a valuable biobank which the company believes now represents one of the world's largest collections of liver cancer blood samples. Glycotest is in advanced negotiations with a number of prospective collaboration partners, further details of which shall be reported in due course.

Dr Ilian Iliev, CEO of NetScientific, and Chair of Glycotest said:

"We welcome this additional funding from Fosun. Complemented by the 2023 CLA, these investments demonstrate strong financial support as Glycotest continues to progress towards commercialisation, including in the US and China.

"EMV Capital securing this third party funding is a further example of our capital efficient investment model, allowing Glycotest to grow without reliance upon the NetScientific balance sheet, and deploying our Value Creation Services team to underpin that growth."

 

The person responsible for arranging the release of this announcement on behalf of the Company is Edward Hooper, General Counsel and Executive Director of the Company.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF REGULATION (EU) NO 596/2014 WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

-Ends-

 

NetScientific

NetScientific

Ilian Iliev, CEO

Via Belvedere Communications

 

 

Panmure Gordon (UK) Limited (NOMAD and Broker)

 

Emma Earl / Freddy Crossley / Will Goode / Mark Rogers (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0)20 7886 2500

Belvedere Communications

John West / Llew Angus / Lily Pearce

 

+44 (0)20 7653 8702

 

About NetScientific

NetScientific plc (AIM: NSCI) is a deep tech and life sciences VC investment group with an international portfolio of innovative companies.

NetScientific identifies, invests in, and builds high growth companies in the UK and internationally. The company adds value through the proactive management of its portfolio, progressing to key value inflection points, and delivering investment returns through partial or full liquidity events.

NetScientific differentiates itself by employing a capital-efficient investment approach, making judicial use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital. The group secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a lean structure that can support a large portfolio.

NetScientific is headquartered in London, United Kingdom, and is admitted to trading on AIM, a market operated by the London Stock Exchange.

www.netscientific.net

About Glycotest

Glycotest is a US based liver disease diagnostics company commercialising new and unique blood tests for life threatening liver cancers and fibrosis-cirrhosis. Founded in 2012 by NetScientific on technology originating at the Baruch S. Blumberg Institute and Drexel University College of Medicine, Glycotest has exclusive, world-wide rights to over 50 patent-protected serum glycoprotein biomarkers, assay technology, and biomarker panels and algorithms that exploit novel sugar-based disease signals.

Glycotest's lead product is its hepatocellular carcinoma (HCC) panel, a biomarker panel, driven by a proprietary algorithm, for curable early-stage HCC, the most common form of primary liver cancer. This has outperformed current standard tests in preliminary clinical studies. Glycotest has also developed tests for liver fibrosis-cirrhosis and cholangiocarcinoma, the second most prevalent form of liver cancer.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURDBGDBGUDDGSD
Date   Source Headline
20th Dec 20184:36 pmRNSPrice Monitoring Extension
20th Dec 201810:28 amRNSForm 8.5 - NetScientific PLC
20th Dec 20187:00 amRNSUpdate on Strategic Review
19th Dec 201811:03 amRNSForm 8.3 - NetScientific Plc
19th Dec 201811:00 amRNSForm 8.3 - NetScientific plc
19th Dec 20189:34 amRNSForm 8.5 - NetScientific PLC
18th Dec 20189:32 amRNSForm 8.5 - NetScientific PLC
13th Dec 20189:06 amRNSForm 8.5 - NetScientific PLC
7th Dec 201810:23 amRNSForm 8.5 - NetScientific PLC
5th Dec 20189:14 amRNSForm 8.5 - NetScientific PLC
4th Dec 20189:50 amRNSForm 8.5 - NetScientific PLC
3rd Dec 201810:31 amRNSForm 8.5 - NetScientific PLC
30th Nov 20183:46 pmRNSForm 8 (OPD) - NetScientific (Offeree)
30th Nov 201811:35 amRNSForm 8.5 - NetScientific PLC
29th Nov 20181:29 pmRNSForm 8.3 - NetScientific Plc
29th Nov 201812:49 pmRNSForm 8.3 - NetScientific Plc
29th Nov 201810:26 amRNSForm 8.5 - NetScientific PLC
28th Nov 20181:46 pmRNSForm 8.3 - NetScientific Plc
28th Nov 20189:51 amRNSForm 8.5 - NetScientific PLC
27th Nov 201812:44 pmGNWInvesco Ltd.: Form 8.3 - Netscientific Plc
27th Nov 201812:34 pmRNSForm 8.3 - NetScientfic Plc
27th Nov 201810:33 amRNSForm 8.5 - NetScientific PLC
27th Nov 20189:36 amRNSForm 8.3 - NetScientific PLC
26th Nov 20183:01 pmRNSAmendment to Executive Director Service Terms
26th Nov 20183:00 pmRNSAnnouncement of Strategic Review
26th Nov 201812:30 pmRNSPDS Announces Merger with Edge Therapeutics
8th Nov 20187:00 amRNSVortex Improves CTC Enumeration with Impedance
1st Nov 20187:00 amRNSVortex and STRATEC Announce Global Partnership
22nd Oct 20181:01 pmRNSGlycotest Completes $10m Series A Round with Fosun
22nd Oct 20187:00 amRNSGlycotest Completes $10m Series A Round with Fosun
28th Sep 20187:00 amRNSInterim Results
20th Sep 20187:00 amRNSProAxsis Immunoassays Selected for Large Trial
15th Aug 20187:00 amRNSWanda Launches CareLink, New Digital Health App
2nd Aug 20187:02 amRNSProAxsis Granted Third Respiratory Field CE Mark
2nd Aug 20187:00 amRNSChange of Adviser
18th Jul 20187:00 amRNSWanda Technology Enhancements
26th Jun 20184:24 pmRNSGrant of Options to Directors
21st Jun 20181:33 pmRNSResult of AGM
6th Jun 20187:00 amRNSBob Englert Appointed CEO of Vortex Biosciences
4th Jun 20187:00 amRNSProAxsis Wins Innovative Business of Year in NI
1st Jun 20187:00 amRNSProAxsis Awarded Invest NI Grant
22nd May 20184:21 pmRNSNotice of AGM and Annual Report & Accounts
21st May 20187:00 amRNSWanda Announces Significant Data with Partner HRS
2nd May 20187:00 amRNSProAxsis to Present New Data at ATS 2018
18th Apr 20185:08 pmRNSDirectors Dealing Notification
16th Apr 20182:04 pmRNSResult of General Meeting
16th Apr 20187:25 amRNSVortex to Present 2 Posters at AACR
11th Apr 201811:39 amRNSResult of Placing
3rd Apr 20184:09 pmRNSPosting of Circular
29th Mar 20187:00 amRNSProposed Placing and Subscription

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.